Emerging drug therapies for benign prostatic hyperplasia
Authors:
- Travis L BullockTBTravis L Bullock
- Gerald L Andriole JrGJGerald L Andriole Jr
- 27 February 2006
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Emerging Drugs
- Vol. 11 (1) , 111-123
Abstract
Benign prostatic hyperplasia (BPH) is the nonmalignant enlargement of the prostate gland caused by increases in number of both epithelial and stromal cells. Clinically, BPH leads to voiding dysfunction, which is most often referred to as lower urinary tract symptoms (LUTS). Historically, the only treatments for LUTS due to BPH were watchful waiting or surgery (transurethral or open prostatectomy). However, over the last 20 years medical therapy has taken a prominent role in the management of BPH. Current medical treatments for BPH include α-adrenergic receptor antagonists, inhibitors of the 5-α reductase enzyme and various phytotherapies. These agents are generally effective and safe; however, many patients are unable to tolerate the side effects or are refractory to medical management and require surgery. In light of this, many potential new therapies for the treatment of BPH are under development. Some represent a variation of current treatments, whereas others target novel molecular pathways within the...Keywords
This publication has 35 references indexed in Scilit:
- Apigenin drives the production of reactive oxygen species and initiates a mitochondrial mediated cell death pathway in prostate epithelial cellsThe Prostate, 2004
- Efficacy and Safety of Long-Term Treatment with the Dual 5α-Reductase Inhibitor Dutasteride in Men with Symptomatic Benign Prostatic HyperplasiaEuropean Urology, 2004
- Alpha-Blocker Therapy Can Be Withdrawn in the Majority of Men Following Initial Combination Therapy with the Dual 5α-Reductase Inhibitor DutasterideEuropean Urology, 2003
- Effects of Bowman–Birk inhibitor concentrate (BBIC) in patients with benign prostatic hyperplasia*†The Prostate, 2001
- Efficacy and Safety of a New Prolonged Release Formulation of Alfuzosin 10 mg Once Daily versus Alfuzosin 2.5 mg Thrice Daily and Placebo in Patients with Symptomatic Benign Prostatic HyperplasiaEuropean Urology, 2000
- A multicentric, placebo‐controlled, double‐blind clinical trial of β‐sitosterol (phytosterol) for the treatment of benign prostatic hyperplasiaBritish Journal of Urology, 1997
- Effect of naftopidil on urethral obstruction in benign prostatic hyperplasia: Assessment by urodynamic studiesThe Prostate, 1994
- Responses to the antagonistic analog of LH-RH (SB-75, cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancerThe Prostate, 1994
- A 12‐Week Placebo‐controlled Double‐blind Study of Prazosin in the Treatment of Prostatic Obstruction due to Benign Prostatic HyperplasiaBritish Journal of Urology, 1992
- Prazosin in the Treatment of Prostatic Obstruction A Placebo‐controlled StudyBritish Journal of Urology, 1987